PT3873883T - Método de síntese - Google Patents
Método de sínteseInfo
- Publication number
- PT3873883T PT3873883T PT208163758T PT20816375T PT3873883T PT 3873883 T PT3873883 T PT 3873883T PT 208163758 T PT208163758 T PT 208163758T PT 20816375 T PT20816375 T PT 20816375T PT 3873883 T PT3873883 T PT 3873883T
- Authority
- PT
- Portugal
- Prior art keywords
- synthesis
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
| GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3873883T true PT3873883T (pt) | 2023-03-24 |
Family
ID=75849570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT208163758T PT3873883T (pt) | 2019-11-07 | 2020-11-09 | Método de síntese |
| PT208163766T PT3844147T (pt) | 2019-11-07 | 2020-11-09 | Compostos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT208163766T PT3844147T (pt) | 2019-11-07 | 2020-11-09 | Compostos |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11643390B2 (pt) |
| EP (3) | EP4180037A1 (pt) |
| JP (3) | JP7423131B2 (pt) |
| KR (2) | KR20230142817A (pt) |
| CN (2) | CN114829340B (pt) |
| AU (2) | AU2020381103B2 (pt) |
| BR (1) | BR112022008919A2 (pt) |
| CA (2) | CA3160337C (pt) |
| DK (1) | DK3844147T3 (pt) |
| ES (2) | ES2940811T3 (pt) |
| HR (2) | HRP20220797T1 (pt) |
| HU (2) | HUE059403T2 (pt) |
| IL (2) | IL292753B2 (pt) |
| MX (1) | MX2022005399A (pt) |
| NZ (1) | NZ788543A (pt) |
| PL (2) | PL3844147T3 (pt) |
| PT (2) | PT3873883T (pt) |
| WO (2) | WO2021089872A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021089872A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Compounds |
| AU2021215811A1 (en) | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
| EP4153564A4 (en) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| PL3902541T3 (pl) * | 2020-06-02 | 2022-11-14 | Small Pharma Ltd | Kompozycje terapeutyczne zawierające deuterowane lub częściowo deuterowane związki n,n-dimetyltryptaminy |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| CN116056762A (zh) | 2020-06-12 | 2023-05-02 | 贝克利心理科技有限公司 | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2023002005A1 (en) * | 2021-07-22 | 2023-01-26 | GH Research Ireland Limited | Method for preparing a tryptamine derivative. |
| EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
| US11697638B2 (en) * | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| WO2023089132A1 (en) | 2021-11-18 | 2023-05-25 | Small Pharma Ltd | Injectable and inhalable formulations |
| WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
| US12012381B2 (en) | 2021-12-30 | 2024-06-18 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US20240101514A1 (en) * | 2022-08-19 | 2024-03-28 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| WO2024079314A1 (en) | 2022-10-13 | 2024-04-18 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| WO2024119075A1 (en) * | 2022-12-01 | 2024-06-06 | ATAI Life Sciences AG | Crystalline forms of n,n-dimethyltryptamine and methods of using the same |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| ATE172723T1 (de) * | 1991-06-21 | 1998-11-15 | Smithkline Beecham Plc | Tryptamin analoga, ihre herstellung und anwendung als 5-ht1-artige rezeptoren oder 5-ht2 rezeptor agonisten |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US6726919B2 (en) | 2000-06-16 | 2004-04-27 | Rtp Pharma, Inc. | Injectable dispersion of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| CN101687788A (zh) | 2006-10-19 | 2010-03-31 | 奥斯拜客斯制药有限公司 | 取代的吲哚 |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| SG183696A1 (en) * | 2007-08-06 | 2012-09-27 | Biotie Therapies Inc | Medicaments comprising nepicastat for use in treating dependence on a substance |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| WO2009049030A1 (en) | 2007-10-09 | 2009-04-16 | Triton Biopharma, Llc | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
| AU2014241430B2 (en) * | 2013-03-14 | 2018-04-26 | Dart Neuroscience (Cayman) Ltd. | Substituted pyridine and pyrazine compounds as PDE4 inhibitors |
| US10336703B2 (en) * | 2015-05-12 | 2019-07-02 | Council Of Scientific And Industrial Research | Process for the synthesis of ivacaftor and related compounds |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| WO2018148605A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| WO2018195455A1 (en) | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| PT3927337T (pt) | 2019-02-22 | 2024-05-17 | Gh Res Ireland Limited | 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para o tratamento da depressão major |
| MX2021009942A (es) | 2019-02-22 | 2021-12-10 | Gh Res Ireland Limited | Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales. |
| CA3130767A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021089872A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Compounds |
| CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
| AU2021215811A1 (en) | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| EP4153564A4 (en) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN116056705A (zh) | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| JP7422474B2 (ja) | 2020-08-28 | 2024-01-26 | サイビン ユーケー リミテッド | 注射用製剤 |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| WO2022069690A2 (en) | 2020-10-02 | 2022-04-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2020
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en active Application Filing
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
- 2020-11-09 CA CA3160334A patent/CA3160334C/en active Active
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Application Discontinuation
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en unknown
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active IP Right Cessation
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-03 IL IL292754A patent/IL292754A/en unknown
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US20230167056A1/en active Pending
- 2023-03-31 US US18/193,866 patent/US20230250059A1/en active Pending
- 2023-11-30 JP JP2023202672A patent/JP2024028798A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292754A (en) | method of synthesis | |
| IL271938A (en) | A method for making synthesis gas | |
| IL271939A (en) | A method for making synthesis gas | |
| IL271941A (en) | A method for making synthesis gas | |
| EP3712130A4 (en) | METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF | |
| ZA201908158B (en) | Novel method for synthesizing amanitins | |
| HUE055242T2 (hu) | Omecamtiv mecarbil szintézise | |
| EP3611171A4 (en) | METHOD OF SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | |
| GB201801768D0 (en) | Synthesis method | |
| GB201701396D0 (en) | Novel alternating-phase synthesis method | |
| IL292210A (en) | An efficient process for the synthesis of 2-amino-5-chloro-n,3-dimethylbenzamide | |
| ZA202101837B (en) | Method for the preparation of synthesis gas | |
| GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
| GB201802839D0 (en) | Method of manufacture | |
| IL291221A (en) | Methods for the synthesis of wolbenzine | |
| GB201903056D0 (en) | Method of oligonucleotide synthesis | |
| PL3755681T3 (pl) | Sposób wytwarzania 4-boronofenyloalaniny | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| PL3498665T3 (pl) | Sposób otrzymywania gazu syntezowego | |
| PT3759082T (pt) | Processo para a síntese de 6-clorometiluracilo | |
| EP3792296C0 (en) | PROCESS FOR THE SYNTHESIS OF POLYETHERS | |
| GB201902779D0 (en) | Method of screening | |
| GB201804905D0 (en) | Cataltic synthesis of biarylic compounds | |
| GB201917499D0 (en) | Methods of synthesis | |
| GB201809404D0 (en) | Method of synthesis |